Continuum Advisory LLC Increases Stake in Eli Lilly and Company $LLY

Continuum Advisory LLC increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 93.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,744 shares of the company's stock after purchasing an additional 2,296 shares during the period. Continuum Advisory LLC's holdings in Eli Lilly and Company were worth $5,690,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Tulsa Wealth Advisors INC raised its holdings in shares of Eli Lilly and Company by 9.1% in the second quarter. Tulsa Wealth Advisors INC now owns 1,499 shares of the company's stock worth $1,798,000 after buying an additional 125 shares during the last quarter. German American Bancorp Inc. grew its holdings in shares of Eli Lilly and Company by 2.0% during the second quarter. German American Bancorp Inc. now owns 15,347 shares of the company's stock valued at $18,408,000 after buying an additional 294 shares during the last quarter. Johnson Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 5.6% during the second quarter. Johnson Wealth Management LLC now owns 320 shares of the company's stock valued at $384,000 after buying an additional 17 shares during the last quarter. Northstar Financial Companies Inc. increased its position in shares of Eli Lilly and Company by 15.0% in the 2nd quarter. Northstar Financial Companies Inc. now owns 2,098 shares of the company's stock valued at $2,517,000 after acquiring an additional 273 shares during the period. Finally, Heritage Trust Co increased its position in shares of Eli Lilly and Company by 20.3% in the 2nd quarter. Heritage Trust Co now owns 3,959 shares of the company's stock valued at $4,749,000 after acquiring an additional 668 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 1.0%

Shares of LLY opened at $1,257.26 on Friday. Eli Lilly and Company has a 52 week low of $694.23 and a 52 week high of $1,292.65. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $1.18 trillion, a price-to-earnings ratio of 42.19, a PEG ratio of 1.47 and a beta of 0.51. The stock's 50-day moving average price is $1,180.14 and its 200-day moving average price is $1,059.82.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.Eli Lilly and Company's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period last year, the company earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's payout ratio is 23.22%.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the firm's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares of the company's stock, valued at $14,131,250. The trade was a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 in the last three months. 0.14% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly will collaborate with Boston-based Chai Discovery on an RNA vaccine platform. The partnership could expand Lilly’s technology and early-stage pipeline, though the financial impact is likely to be longer term. Lilly to work with Boston-based firm to develop RNA vaccine platform
• Positive Sentiment: Recent coverage continues to highlight Lilly’s momentum in obesity treatment, with its products reportedly outpacing Novo Nordisk’s offerings. This reinforces expectations for sustained demand and supports LLY’s growth narrative. Eli Lilly's obesity treatments outpace Novo Nordisk
• Positive Sentiment: Analyst-focused coverage identifies Eli Lilly as a leading candidate for significant earnings growth and a potential buy point as the broader market rebounds. These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Tops Buy Point
• Neutral Sentiment: Lilly completed or advanced several clinical studies, including trials involving hidradenitis suppurativa, lebrikizumab, LY4178256 and eloralintide. The updates broaden the pipeline, but no decisive efficacy or regulatory results were provided. Lilly clinical-trial updates
• Neutral Sentiment: Discussion of a possible stock split reflects the sharp rise in LLY’s share price, but a split would not change the company’s fundamental value or earnings outlook. Stock Split Watch: Is Eli Lilly Stock Next?
• Negative Sentiment: Lilly continues to face competition from Novo Nordisk in the emerging oral GLP-1 market. The race creates substantial growth potential but also raises execution and market-share risks. Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race?

Analyst Ratings Changes

LLY has been the subject of a number of research reports. Guggenheim lifted their price target on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a research report on Monday, July 13th. Truist Financial increased their price objective on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a "buy" rating in a report on Friday, August 7th. Wall Street Zen upgraded Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 15th. Barclays lifted their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an "overweight" rating in a report on Monday, May 4th. Finally, Wolfe Research reiterated an "outperform" rating and issued a $1,350.00 target price on shares of Eli Lilly and Company in a research report on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $1,292.18.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source